Cipla USA Inc. the wholly owned subsidiary of Cipla Limited(BSE: 500087; NSE: CIPLA; and hereafter referred to as "Cipla") today announced the launch of Liraglutide Injection, 18 mg/3 mL (6 mg/mL) single-patient-use prefilled pens, the generic equivalent of Saxenda® (liraglutide injection).
This milestone builds on the recent Abbreviated New Drug Approval (ANDA) by United States Food & Drugs Administration (USFDA) obtained by its partner, Orbicular, for Liraglutide Injection(generic Saxenda®). Cipla will lead the product’s marketing and distribution, enabling broad access and reliable availability for patients. The company is set to commence the launch on an immediate basis.
Liraglutide Injection is a complex injectable peptide delivered through a multidose injector pen drug-device combination. It is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in patients meeting defined clinical criteria.
Commenting on the launch, Achin Gupta, Global CEO & MD Designate, Cipla, said, “This development represents a key milestone in our peptide portfolio and strengthens our differentiated U.S. offering. We remain focused on expanding access to high-quality, affordable medicines at scale, supported by disciplined execution and collaboration.”
Marc Falkin, CEO, Cipla North America, added: “We appreciate Orbicular’s work in achieving FDA approval, which enables our immediate U.S. launch. With Cipla’s strong commercial infrastructure and deep channel relationships, we are positioned to drive broad availability for customers and patients. This milestone strengthens Cipla’s position as one of the few companies offering generic versions of both Victoza® and Saxenda® in the U.S.”
GLP-1 receptor agonists have emerged as one of the fastest-growing therapeutic classes globally, driven by the rising prevalence of obesity and metabolic disorders, strong clinical outcomes, and increasing physician adoption.
About Glucagon-Like Peptide-1 (GLP-1) Glucagon-like peptide-1 (GLP-1) therapies help regulate blood glucose levels and promote weight loss by enhancing insulin secretion, suppressing glucagon release, delaying gastric emptying, and reducing food intake supporting improved metabolic control and weight management outcomes.
About Liraglutide
Liraglutide is a synthetic analog of the human GLP-1 hormone and is administered as a once-daily subcutaneous injection. The molecule was first approved for medical use in the European Union in 2009 and in the United States in 2010. Liraglutide received U.S. FDA approval for chronic weight management in adults in 2014, with subsequent approvals in defined pediatric populations.
